Phase I study of weekly oxaliplatin in relapsed or refractory pediatric solid malignancies

Journal of Clinical Oncology

Volumn 26, Issue 27, 2008, Pages 4394-4400

  Geoerger, Birgit ^a   Doz, François ^a   Gentet, Jean Claude ^a   Mayer, Michele ^a   Landman Parker, Judith ^a   Pichon, Fabienne ^a   Chastagner, Pascal ^a   Rubie, Hervé ^a   Frappaz, Didier ^a   Le Bouil, Anne ^a   Gupta, Sunil ^a   Vassal, Gilles ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

OXALIPLATIN;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BONE PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; COUGHING; DEHYDRATION; DIARRHEA; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; DYSESTHESIA; FEMALE; FEVER; HEADACHE; HUMAN; HYPERESTHESIA; LARYNX SPASM; LIMB PAIN; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE CRAMP; NAUSEA; NEUROBLASTOMA; NEUTROPENIA; OSTEOSARCOMA; OTOTOXICITY; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PRURITUS; RECOMMENDED DRUG DOSE; SCHOOL CHILD; SENSORY NEUROPATHY; SEPSIS; SOLID TUMOR; SUPERIOR CAVA VEIN OBSTRUCTION; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT FAILURE; VOMITING;

ABDOMINAL PAIN; ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EVOKED POTENTIALS, SOMATOSENSORY; FEASIBILITY STUDIES; FEVER; HUMANS; INFANT; MAXIMUM TOLERATED DOSE; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; PARESTHESIA; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 52449126408     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.16.7585     Document Type: Article

References (19)

1. André T, Boni C, Mounedji-Boudiaf L, et al: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343-2351, 2004
2. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004
3. Rothenberg ML, Oza AM, Bigelow RH, et al: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial. J Clin Oncol 21:2059-2069, 2003
4. Raymond E, Faivre S, Woynarowski JM, et al: Oxaliplatin: Mechanism of action and antineoplastic activity. Semin Oncol 25:4-12, 1998
5. Raymond E, Faivre S, Chaney S, et al: Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 1:227-235, 2002
6. Faivre S, Chan D, Salinas R, et al: DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem Pharmacol 66:225-237, 2003
7. Hartmann JT, Lipp HP: Toxicity of platinum compounds. Expert Opin Pharmacother 4:889-901, 2003
8. Bertolini P, Lassalle M, Mercier G, et al: Platinum compound-related ototoxicity in children: Long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol 26:649-655, 2004
9. Lanvers-Kaminsky C, Krefeld B, Dinnesen AG, et al: Continuous or repeated prolonged cisplatin infusions in children: A prospective study on ototoxicity, platinum concentrations, and standard serum parameters. Pediatr Blood Cancer 47:183-193, 2006
10. Freilich RJ, Kraus DH, Budnick AS, et al: Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue. Med Pediatr Oncol 26:95-100, 1996
11. Parsons SK, Neault MW, Lehmann LE, et al: Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma. Bone Marrow Transplant 22:669-674, 1998
12. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000
13. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment (offset publication no. 48). Geneva, Switzerland, World Health Organization, 1979
14. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47: 207-214, 1981
15. Mathé G, Kidani Y, Triana K, et al: A phase I trial of trans-1-diaminocyclohexane oxalato-platinum (l-OHP). Biomed Pharmacother 40:372-376, 1986
16. Extra JM, Espie M, Calvo F, et al: Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 25:299-303, 1990
17. Spunt SL, Freeman BB III, Billups CA, et al: Phase I clinical trial of oxaliplatin in children and adolescents with refractory solid tumors. J Clin Oncol 25:2274-2280, 2007
18. Fouladi M, Blaney SM, Poussaint TY, et al: Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: A pediatric brain tumor consortium study. Cancer 107:2291-2297, 2006
19. 2 q3w dosage regimen - Report PKM2983. United Kingdom, Sanofi Recherche, September 08, 1998 (available upon request)